Article
In silico evaluation of selected triterpenes as potential inhibitors of BRAF and BRAFV600E kinases for cancer treatment.
Journal of molecular modeling - 27 Apr 2026
Aguilera-Durán Giovanny, Rivera-Vargas Alex, Hernández-Estrada Beatriz, Alvarez-Baltazar J M, Loera-García Brenda V, Cuevas-Flores Ma Del Refugio, Romo-Mancillas Antonio
Abstract excerpt
CONTEXT: BRAF kinases are involved in cancer cell survival and metastasis. Mutations in BRAF are frequent in several types of cancer, occurring in more than 50% of melanomas, 50-70% of thyroid cancers, 15% of colorectal cancers, and 5-8% of non-small-cell lung cancers. The most prevalent mutation is V600E. Vemurafenib and dabrafenib are two selective BRAF inhibitors approved by the FDA for clinical use. However,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.